Navigation Links
IRS Proposed Regulations on Orphan Drug Exclusion from Drug Tax Stand to Harm Future Development of Treatments for Rare Disease Patients
Date:8/22/2011

ANNAPOLIS, Md., Aug. 22, 2011 /PRNewswire/ -- The Plasma Protein Therapeutics Association (PPTA) believes the Internal Revenue Services' issuance of temporary and proposed regulations implementing the annual pharmaceutical fee undermines patients with rare diseases and fails to take into account concerns expressed by leading consumer organizations and Congress. The Agency's narrow definition of an "orphan drug" disproportionally affects the highly specialized segment of biological plasma protein therapies and puts the development of drugs and therapies for rare diseases at risk.

The IRS regulations continue to require that a manufacturer claim the Orphan Drug Act tax credit established in section 45C of the Internal Revenue Code in order for a drug to qualify as an "orphan drug" for the purpose of excluding its sales from calculations that determine a manufacturer's total annual pharmaceutical fee liability. This stance acutely affects plasma protein therapies. The majority of these therapies face significant regulatory hurdles in obtaining "orphan designation" as a result of there being multiple unique, non-interchangeable brands in most therapeutic classes to meet the needs of a variety of rare disease patient populations. Typically, only the first to market drug or therapy in a class receives orphan drug designation from the U.S. Food and Drug Administration (FDA), which is required to quality for the Orphan Drug Act tax credit.

"By creating an exemption to the fee for orphan drugs, as well as the long history of incentives initiated with the enactment of the Orphan Drug Act, there is clearly a longstanding congressional interest in encouraging the research and development of drugs and biologicals to treat rare diseases;
'/>"/>

SOURCE Plasma Protein Therapeutics Association (PPTA)
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Alliance Pharmaceutical Corp. Announces Approval of Proposed Actions at Annual Shareholders Meeting
2. U.S. Naval Medical Research Center Resubmits IND Application for Proposed Op RESUS Clinical Trial in Trauma Patients in the Battlefield Setting
3. U.S. Naval Medical Research Center Resubmits IND Application for Proposed RESUS Clinical Trial in Trauma Patients in the Out-of-Hospital Setting
4. U.S. Naval Medical Research Center Proposed RESUS Clinical Trial in Trauma Patients Remains on FDA Hold
5. ALP Life Sciences, LLC Announces Nanoveson(TM) Patent Filing and Whitepaper Availability on Proposed Therapy for Non-Alcoholic Fatty Liver Disease (NAFLD) and Comorbid Diseases
6. Savient Pharmaceuticals Announces Proposed Public Offering of Common Stock
7. Pulmo BioTech Inc. Announces Letter of Intent Regarding Proposed License of its Pulmonary Vascular Diagnostic Product Candidate PulmoBind(TM)
8. Relators Attorneys Comment On AtriCure/DOJ Proposed Settlement
9. Trius Therapeutics Files Registration Statement for Proposed Initial Public Offering
10. ISS/Risk Metrics Group and Glass Lewis Recommend VaxGen Stockholders Vote For Proposed Merger With OXiGENE
11. Quest Diagnostics Incorporated Announces Proposed Senior Notes Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... 1, 2015 CytRx Corporation (NASDAQ: ... specializing in oncology, today announced that Steven ... and David Haen , Vice President of ... corporate overview at two significant investment conferences in ... industries: the FBR & Co. Second Annual Health ...
(Date:9/1/2015)... 1, 2015 Pressure BioSciences, Inc. (OTCQB: ... the development and sale of broadly enabling, pressure ... worldwide life sciences industry, today announced the publication ... Company,s PCT Platform could play a significant role ... role is based on PCT,s unique ability to ...
(Date:9/1/2015)... , September 1, 2015 ... company, today announces that it has appointed Hilde ... Non-Executive Directors to its Board of Directors, effective immediately. ... years of experience in pharma and biotech and is ... a Sanofi company. Previously her role was Vice President ...
Breaking Medicine Technology:CytRx Announces Participation at FBR & Co. Second Annual Health Conference and Rodman & Renshaw 17th Annual Global Investment Conference 2CytRx Announces Participation at FBR & Co. Second Annual Health Conference and Rodman & Renshaw 17th Annual Global Investment Conference 3CytRx Announces Participation at FBR & Co. Second Annual Health Conference and Rodman & Renshaw 17th Annual Global Investment Conference 4New Scientific Publication Suggests Pressure BioSciences' PCT Platform Could Play Significant Role in Personalized/Precision Medicine 2New Scientific Publication Suggests Pressure BioSciences' PCT Platform Could Play Significant Role in Personalized/Precision Medicine 3New Scientific Publication Suggests Pressure BioSciences' PCT Platform Could Play Significant Role in Personalized/Precision Medicine 4New Scientific Publication Suggests Pressure BioSciences' PCT Platform Could Play Significant Role in Personalized/Precision Medicine 5BerGenBio Appoints Non-Executive Directors 2
... Pricing of $500 Million of Senior Notes in Connection with... -- ARDEE, Ireland, Sept. 24 ... ... lpUnit=,PRN,; --> ... { var s = ,; var first_result; // Results are keyed by longUrl, so we need to ...
... Misonix, Inc. (Nasdaq: MSON ), a ... technology, which worldwide is used for acute health conditions, ... ended June 30, 2010 financial results on Tuesday, September ... Officer and Richard Zaremba, Senior VP and Chief Financial ...
Cached Medicine Technology:Warner Chilcott Announces Pricing of $500 Million of Senior Notes in Connection with Agreement to Acquire U.S. Rights to Enablex® 2Warner Chilcott Announces Pricing of $500 Million of Senior Notes in Connection with Agreement to Acquire U.S. Rights to Enablex® 3Warner Chilcott Announces Pricing of $500 Million of Senior Notes in Connection with Agreement to Acquire U.S. Rights to Enablex® 4Warner Chilcott Announces Pricing of $500 Million of Senior Notes in Connection with Agreement to Acquire U.S. Rights to Enablex® 5Warner Chilcott Announces Pricing of $500 Million of Senior Notes in Connection with Agreement to Acquire U.S. Rights to Enablex® 6Warner Chilcott Announces Pricing of $500 Million of Senior Notes in Connection with Agreement to Acquire U.S. Rights to Enablex® 7Warner Chilcott Announces Pricing of $500 Million of Senior Notes in Connection with Agreement to Acquire U.S. Rights to Enablex® 8Misonix Schedules Fourth Quarter and Fiscal 2010 Financial Results Conference Call; September 28, 2010 at 4:30 p.m. Eastern 2
(Date:9/1/2015)... MA (PRWEB) , ... September 01, 2015 , ... The ... little-known and incurable disease, facioscapulohumeral muscular dystrophy (FSHD), will be the beneficiary of a ... the same mission – to raise awareness of the FSH Society and further FSHD ...
(Date:9/1/2015)... ... September 01, 2015 , ... METTLER TOLEDO is pleased to ... the Connectivity Kit, EasySampler data is automatically transferred to, and reported with, the ... touchscreen platform. , EasySampler fully automates the sampling process including sampling ...
(Date:9/1/2015)... (PRWEB) , ... September 01, 2015 , ... ... September 9, 2015 from 5:00 to 8:00 pm at the Marriott Indianapolis Downtown, ... groups with career opportunities will be attending from across the country. All specialties ...
(Date:9/1/2015)... ... September 01, 2015 , ... Dr. Trace Curry successfully placed one of ... In the last month the FDA has approved two intra-gastric balloons, the ORBERA ... represent the first incisionless, reversible, weight loss procedures available to Americans. , ...
(Date:9/1/2015)... ... September 01, 2015 , ... Elizabeth Callahan, MD, founder ... the first in the area to offer RADIESSE® filler treatment for volume loss in ... prominence of tendons and veins in the hands, delivering smooth, natural-looking results that can ...
Breaking Medicine News(10 mins):Health News:FSH Society Beneficiary of Variety of Fall Fundraising Events 2Health News:FSH Society Beneficiary of Variety of Fall Fundraising Events 3Health News:New Technology Allows Unattended Sampling and Synthesis of Chemical Reactions 2Health News:New Technology Allows Unattended Sampling and Synthesis of Chemical Reactions 3Health News:PracticeMatch to Host Physician Career Fair at the Marriott Indianapolis Downtown on September 9, 2015 2Health News:PracticeMatch to Host Physician Career Fair at the Marriott Indianapolis Downtown on September 9, 2015 3Health News:PracticeMatch to Host Physician Career Fair at the Marriott Indianapolis Downtown on September 9, 2015 4Health News:Dr. Trace Curry Performs First ORBERA™ Intra-gastric Balloon in Ohio at JourneyLite, a New Incisionless Option For The Treatment of Obesity 2Health News:SkinSmart Dermatology in Sarasota is Now Offering RADIESSE to Rejuvenate Hands 2Health News:SkinSmart Dermatology in Sarasota is Now Offering RADIESSE to Rejuvenate Hands 3
... inheritable genes to enable people to produce more ‘perfect’ ... and on being human, warns a leading US science ... out great hope for IGM technology, which offers them ... Disease and schizophrenia on to their children.// ,However, ...
... the risk of pancreatic cancer in both sexes,while moderate ... obese individuals,says Dr. Dominique S. Michaud the head ... National Cancer Institute in Rockville, Maryland and colleagues collected ... 75 years of age, who participated in the Health ...
... popular belief, the heart can actually repair itself by growing new ... researchers in New York and Italy. Dr. Piero Anversa and colleagues ... heart muscle cells called myocytes continued to divide after a heart ... examined the hearts of 13 people who died within a few ...
... patients suffering from Angina may have some new treatment ... Angina, a common cardiovascular disorder affecting millions of people ... by blood vessels too clogged to get oxygen-rich blood ... either medication or for more serious cases, rerouting the ...
... piglets last week could significantly increase the success rate ... research has indicated that rejection of animal cells and ... to the presence of the gene alpha 1,3 galactosyl ... a sugar// to the surface of pig cells, flagging ...
... A new technique to keeping heart arteries flowing easily ... solving a major weakness of the common procedure.Doctors ... - the drug-coated stent. In testing on 30 patients ... percent effective, an accomplishment almost unheard of in medicine.// ...
Cached Medicine News:Health News:Perfect babies boon or a bane? 2Health News:Antibiotic, Gene Therapy Help Treat Angina 2Health News:Antibiotic, Gene Therapy Help Treat Angina 3Health News:Xenotransplantation “breakthrough” 2Health News:A ray of hope in Angioplasty dilemma 2
Inquire...
Calss II Type B2 Biological Safety Cabinet...
External Calibration Only. Built-in RS232 Interface, Shimadzu WindowsDirect communication function. 120/240V A/C adapter....
... Semi-Micro balance. Built-in, motor-driven internal ... Performs Fully Automatic Self-Calibration when temperature ... intervals. Menu-selected weighing parameters, plug-in ... function keypads make this balance series ...
Medicine Products: